✦ LIBER ✦

Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in medical patients with enoxaparin (MEDENOX) trial

✍ Scribed by Alexander G.G. Turpie

Book ID: 113974562
Publisher: Elsevier Science
Year: 2000
Tongue: English
Weight: 630 KB
Volume: 86
Category: Article
ISSN: 0002-9149
DOI: 10.1016/s0002-9149(00)01481-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCV17: ECONOMIC EVALUATION OF ENOXAPARIN

PCV17: ECONOMIC EVALUATION OF ENOXAPARIN IN PATIENTS WITH ACUTE MEDICAL ILLNESS: AN ITALIAN ECONOMIC STUDY FROM THE MEDENOX TRIAL

✍ M Nuijten; P Berto; J Kosa; V Nadipelli 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 67 KB

Benefits of deep-vein thrombosis prophyl

Benefits of deep-vein thrombosis prophylaxis in the nonsurgical patient: The MEDENOX trial

✍ Alexander T Cohen; Htwe M Zaw; Raza Alikhan 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 794 KB

Venous thromboembolism prophylaxis in th

Venous thromboembolism prophylaxis in the medically ill patient

✍ Michota, Franklin A 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 192 KB

PCV22: COST-EFFECTIVENESS OF ENOXAPARIN

PCV22: COST-EFFECTIVENESS OF ENOXAPARIN AS VENOUS THROMBOEMBOLISM PROPHYLAXIS IN ACUTELY ILL MEDICAL PATIENTS

✍ G de Lissovoy; P Subedi; V Nadipelli 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 67 KB

PCV39 ECONOMIC EVALUATION OF THE MEDENOX

PCV39 ECONOMIC EVALUATION OF THE MEDENOX (PROPHYLAXIS IN MEDICAL PATIENTS WITH ENOXAPARIN) TRIAL FROM THE PERSPECTIVE OF HOSPITALS IN GERMANY: RESULTS OF A SUBGROUP ANALYSIS

✍ PK Schädlich; M Kentsch; M Weber; W Kämmerer; V Nadipelli; E Huppertz; JG Brecht 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB

Cost utility of substituting enoxaparin

Cost utility of substituting enoxaparin for unfractionated heparin for prophylaxis of venous thrombosis in the hospitalized medical patient

✍ Luci Leykum; Jacqueline Pugh; David Diuguid; Kyriakos Papadopoulos 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 180 KB

## Abstract ## BACKGROUND Both heparin and enoxaparin are effective for the prevention of venous thromboembolism (VTE) in medical patients. On the basis of price, heparin appears preferable because it is less expensive. However, choosing enoxaparin may have greater cost utility when the outcomes o